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disutility may be used in cost-utility analysis to estimate treatment outcomes for 
T2DM.
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Objectives: Reimbursement agencies in Europe have questioned the benefits 
offered by rapid-acting analog insulin (RAAI) over regular human insulin (RHI) in 
type 1 diabetes (T1D). This analysis evaluates the cost-effectiveness of RAAI rela-
tive to RHI using a T1D-specific health economic model developed using recently 
published clinical data. MethOds: The PRIME Diabetes Model — a patient-level, 
discrete-event simulation — was used to evaluate health and cost outcomes in 
100,000 people with T1D in the UK setting over a 50-year time horizon. The mean 
cohort characteristics (age 35.2 years, duration of diabetes 13.7 years, HbA1c 7.4%, 
body mass index 23.8 kg/m2, and 61.3% male) and insulin doses were derived 
from a clinical trial comparing RAAI with RHI, both with basal insulin glargine. 
In the base case, RHI changed HbA1c by −0.312%, and a meta-analysis indicated 
that the additional impact of RAAI was −0.09%. Compared with RHI, the relative 
rate of hypoglycemic events with RAAI was 1.07 (non-severe daytime), 0.51 (non-
severe nocturnal), and 0.80 (severe). An annual discount rate of 3.5% was applied 
to health and cost outcomes. Results: RAAI was associated with increased qual-
ity of life, providing an extra 0.68 quality-adjusted life years (QALYs) per patient 
compared with RHI (11.54 vs. 10.86). QALY gains were driven by reduced noctur-
nal and severe hypoglycemia. Reductions in hospitalizations related to severe 
hypoglycemia also contributed to a slight survival benefit with RAAI (19.4% vs. 
18.7% at 50 years). Direct medical costs were higher with RAAI than with RHI, 
though the mean cost difference per patient was small: GBP 3,473. The incremen-
tal cost-effectiveness ratio was estimated at GBP 5,103 per QALY gained. Results 
were robust under probabilistic sensitivity analyses. cOnclusiOns: In T1D, RAAI 
is associated with beneficial patient outcomes compared with RHI and is esti-
mated to be cost-effective in the UK given generally accepted willingness-to-pay 
thresholds.
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Objectives: To evaluate the cost effectiveness and cost-utility the one-step scheme, 
recommended by the International Association of Diabetes and Pregnancy Study 
Group (IADPSG), compared with the two-step scheme, recommended by the American 
Diabetes Association (ADA) for screening and diagnosis of gestational diabetes mel-
litus in Colombia MethOds: We designed a decision tree model that compared the 
effectiveness, based on a systematic literature review, and expected costs for each 
alternative. Outcomes included correctly diagnosed cases, pre-term births and other 
obstetric complications. Utility weights, in QALYs, were derived from the literature. 
The analysis was conducted from a third-party payer perspective, considering only 
direct medical costs both for normal pregnancy and associated complications, based 
on base cases designed by an expert panel, and resource use turned into prices using 
official tariff manuals. Time frame was from gestational week 24 until one month 
after delivery. Results were subject to univariate and probabilistic sensitivity analyses. 
Costs were in 2014 Colombian pesos (1 euro = COP 2,660). Results: By using the 
one-step scheme average costs per pregnant woman were similar for the one-step 
(€ 476), or the two-step (€ 500) schemes. In terms of adverse maternal and neona-
tal outcomes, the one-step scheme shows better clinical performance and slightly 
more QALYs gained (0.06). A correct diagnosis would be reached in 921 and 853 
women per thousand, respectively. One-step scheme averted 8 pre-term births 
per thousand. The results withstood the sensitivity analyses. cOnclusiOns: 
A one-step scheme should lead to slightly lower expected costs and better clinical 
outcomes.
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Objectives: Guidelines for the management of type 1 diabetes advocate treat-
ment regimens that reduce the frequency of hypoglycaemic episodes, while 
maintaining blood glucose levels as near normal as is feasible. Therapy-related 
consequences of treatment, such as weight gain and hypoglycaemia act as a bar-
rier to optimal glycaemic control and impact the cost-effectiveness of therapies. 
This study sought to ascertain the respective contribution of changes in hypogly-
caemia, weight and glycosylated haemoglobin (HbA1c) to quality-adjusted sur-
vival among a type 1 diabetic population. MethOds: The Cardiff Type 1 Diabetes 
Model was utilised to model an EDIC-type population: age 33.3 years, 47% female, 
with baseline BMI 25.8 kg/m2, HbA1c 8.2% and duration of diabetes 12.1 years. 
Baseline hypoglycaemia rates and utility decrements associated with macro- and 
microvascular complications, hypoglycaemia and weight change were sourced 
from the published literature. Treatment related changes in symptomatic hypo-
glycaemia (±10%, 20% or 30%) and weight (±1kg, 2kg or 3kg) were applied over 
the first 6 months of treatment and quality-adjusted life years (QALYs) evalu-
domized clinical trial (Nauck et al. 2011, 52 weeks) comparing DAPA+MET vs 
SU+MET was considered to determine the proportion of patients achieving 7 clini-
cally relevant composite endpoints (CEP) including: changes in HbA1c, weight, 
hypoglycaemic events and systolic blood pressure (SBP). Additionally, it was cal-
culated the cost per patient that achieved CEP. Results: Patients treated with 
DAPA+MET showed a higher probability to achieve different CEP than SU+MET. In 
the case of CEP combining HbA1c< 7%, no hypoglycemic events and ≥ 5% weight 
loss: 96% DAPA+MET and 4% SU+MET achieved it and were approximately 22 
times more likely to achieve this CEP vs. SU+MET. In the case of CEP combining 
HbA1c< 7%, no hypoglycaemic events and ≥ 3% weight loss: 92% patients treated 
with DAPA+MET and 8% with SU+MET achieved it and the probability was 11 times 
higher with DAPA+MET. And in CEP combining HbA1creduction ≥ 0.5%, weight loss 
≥ 3% and SBP reduction ≥ 3 mmHg: 91% patients treated with DAPA+MET achieved 
it and 9% with SU+MET and the probability was 10 times higher. The cost per 
patients achieved different CEP was between € 3,058 and € 9,386 with DAPA+MET, 
whereas with SU+MET was between € 5,125and € 82,005, showing that sulfony-
lureas use could result in a achieved CEP cost per patient up to 8,7 times more 
expensive than treating patients with DAPA. cOnclusiOns: The analysis showed 
that more patients treated with DAPA+MET in comparison with SU+MET achieved 
the CEP considered after one year of treatment, and it was also associated with 
a lower cost per patient.
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Objectives: Canagliflozin, an agent that inhibits sodium glucose co-transporter 2, 
decreases glucose levels by lowering the renal threshold for glucose excretion, thereby 
increasing urinary glucose excretion (UGE). Increased UGE lowers glucose and reduces 
body weight and systolic blood pressure (SBP). In contrast, dipeptidyl peptidase-4 
inhibitors such as sitagliptin lower glucose but are not associated with weight loss 
or SBP reduction, and sulfonylureas (glimepiride) are associated with weight gain 
and hypoglycaemia risk. The objective of this analysis was to assess the treatment 
costs of canagliflozin versus glimepiride or sitagliptin in patients with type 2 diabetes 
mellitus (T2DM) inadequately controlled with metformin from the Italian National 
Health Service perspective. MethOds: Two CMAs were conducted to compare the 
mean annual direct costs of a patient with T2DM receiving canagliflozin (100 or 300 
mg) or glimepiride (5,6 mg) or sitagliptin (100 mg). Both analyses estimated 12-month 
annual patient costs. Treatment effects and adverse event rates were sourced from 
head-to-head studies (ie, direct comparisons) in dual therapy with background met-
formin in the canagliflozin Phase 3 program. In both analyses, only direct medical 
costs (eg, antihyperglycaemic and other drugs, hospitalizations after hypoglycaemic 
events, blood glucose monitoring) were considered. The analysis also included direct 
healthcare cost savings associated with weight reduction. Italian costs were sourced 
from the literature and local sources. Uncertainty was assessed by deterministic sen-
sitivity analysis. Results: Canagliflozin 100 and 300 mg showed lower expected costs 
(€ 2.785,46 and € 2.979,52, respectively) versus glimepiride (€ 3.167,90). Canagliflozin 100 
and 300 mg also showed lower expected costs (€ 2.820,05 and € 3.013,96, respectively) 
versus sitagliptin (€ 3.030,38). cOnclusiOns: This CMA showed that canagliflozin 
(100 or 300 mg) is a cost-saving strategy compared with glimepiride or sitagliptin in 
the treatment of patients with T2DM inadequately controlled with metformin from 
the perspective of the Italian National Health Service.
PDB73
hEalth utilitiEs assoCiatED With hyPoglyCEmiC EvEnts in tyPE 2 
DiaBEtEs mEllitus (t2Dm) PatiEnts RECEiving Basal-Bolus insulin 
thERaPy
Ionova T1, Nikitina T1, Kurbatova K2
1National Pirogov Medical Surgical Center, Moscow, Russia, 2Multinational Center for Quality of 
Life Research, Saint-Petersburg, Russia
Objectives: Hypoglycemia is one of the major limiting factors in the management 
of T2DM patients on insulin. Disutility for different types of hypoglycemic events 
is an important component of cost-utility analysis. The aim of this study was to 
determine disutility for mild, severe and nocturnal hypoglycemic events in T2DM 
patients receiving insulin therapy. MethOds: One thousand T2DM patients on 
insulin (mean age – 61.1 yrs; male/female – 265/735) were included in the real-
world study aimed to measure their quality of life and hypoglycemia burden. All 
the patients completed SF-36 questionnaire. To determine the utility value for each 
patient SF-6D questionnaire based on the SF-36 was used. In total, 631 patients 
recorded episodes of hypoglycemia during the last month. The patients without 
hypoglycemia and patients with mild, severe or nocturnal hypoglycemic events were 
analyzed. The average utility value for each group was calculated with adjustment 
for gender, age, comorbidities, late complications, glycosylated hemoglobin level. 
The disutility for one episode of each type of hypoglycemia was determined as 
the difference between the average utility for patients without hypoglycemia and 
average utility for patients with corresponding type of hypoglycemia. Results: The 
utility value for patients without hypoglycemia was 0.680; for patients with mild 
hypoglycemia – 0.668; for patients with severe hypoglycemia – 0.595; for patients 
with nocturnal hypoglycemic event – 0.657. Patients without hypoglycemia had the 
highest utility value whereas patients with severe hypoglycemia the lowest one. 
Disutility value for mild hypoglycemic event was 0.012, severe event – 0.085, and 
nocturnal hypoglycemic event – 0.023. cOnclusiOns: The values of health utility 
and disutility for T2DM patients receiving insulin therapy were obtained from the 
real-world data. Severe hypoglycemia was associated with greater disutility than 
non-severe and nocturnal hypoglycemia. The obtained values of health utility and 
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within and between the MTM members and controls were measured (difference-
in-differences (DID) analysis). Results: 2382 patients (MTM group: n= 201, mean 
age= 75,44%male; control group: n= 2181,mean age= 74,48%male) in the diabetes 
cohort and 9751 patients (MTM group: n= 563, mean age= 76,39% male; control 
group: n= 9188, mean age= 75,40% male) in the hypertension cohort were included. 
For patients in diabetes cohort, the MTM group had pre-post increase in PDC by 
5.19% (P= 0.05), while the control group had decrease of 2.82% (P< 0.01) (DID= 8.03%; 
P= 0.003). For patients in hypertension cohort, the MTM group had pre-post 
increase in PDC by 17.33% (P< 0.01), while the control group had increase of 9.64% 
(P< 0.01) (DID= 7.67%; P< 0.01). The PDC finding was confirmed with regression 
analyses with propensity score adjustment showing the MTM groups had a sig-
nificant increase in pre-post PDC for hypertension, as compared with the control 
group, while controlling for baseline characteristics (P= 0.01). cOnclusiOns: This 
study found that the pharmacist-managed MTM program significantly increased 
medication adherence in Medicare MAPD patients with hypertension, as compared 
with a control group.
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Objectives: Oral Antidiabetics (OAD) have been shown to reduce the risk of mor-
tality, particularly among metformin users, which had risk reductions of 36% for 
cardiovascular-related death and 33-40% for all-cause mortality. However, very few 
studies have assessed adherence to OAD and all-cause mortality. A population-based 
nested case-control study design was used to investigate the relationship between 
adherence to OAD and all-cause mortality among incident users of OAD. MethOds: 
Incident OAD users were identified using healthcare databases of residents covered by 
the public drug insurance plan of the Province of Quebec, Canada. Patients initiated 
OAD therapy between 2000 and 2009 and were aged 45-85 years at cohort entry. A 
nested case-control design was conducted to study mortality occurrence. Each case 
was matched to 10 controls by gender, age and duration of follow-up. The adherence 
to OAD was measured by calculating the medication possession ratio. Conditional 
logistic regression models were used to estimate the association between adherence 
to OAD and all-cause mortality adjusting for various potential confounders. Results: 
The cohort included 63,859 incident OAD users at entry: mean age was 68 years old, 
45% were male, 37% had coronary artery disease, 82% had hypertension, and 62% 
dyslipidemia. Most patients initiated their OAD treatment with biguanides (78%) 
and sulfonylureas (12%). The average follow up time was 48 months. Among those 
deemed adherent, the risk of mortality was decreased compared to nonadherent (Rate 
ratio: 0.67 [95%CI 0.64-0.70]). The likelyhood for mortality was higher for patients with 
heart failure (1.56 [1.49-1.65]), ≥ 2 cardiovascular diseases (1.45 [1.39-1.52]), amputa-
tions (2.03 [1.42-2.91]), chronic viral infections (1.73 [1.44-2.07]), corticosteroid use 
(1.69 [1.56-1.89]), and ≥ 1 hospital admissions (1.73 [1.65-1.80]). Conversely, mortality 
was least likely for patients with dyslipidemia (0.76 [0.73-0.79]), and hypertension 
(0.88 [0.83-0.94]). cOnclusiOns: Adherence to OAD seems to be associated with a 
risk reduction of mortality. Further research is needed to confirm this risk. Residual 
confounding may remain a potential issue.
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Objectives: To assess basal insulin persistence, associated factors, and economic 
outcomes for insulin-naïve people with Type 2 diabetes mellitus (T2DM) in Japan 
using health insurance claims data. MethOds: People aged ≥ 18 years diagnosed 
with T2DM with their first claim for basal insulin between 5/2006-4/2013 (index 
date), no insulin use before index date, and continuous insurance coverage for 6 
months before (baseline) and 12 months after index date were selected from the 
Japan Medical Center Database. Based on whether there were ≥ 30 day-gaps in basal 
insulin use, patients were classified as continuers (no gap), interrupters (≥ 1 prescrip-
tion after gap), and discontinuers (no prescription after gap). Multinomial logistic 
regression model was used to identify factors associated with persistence. Annual 
healthcare resource use and costs were compared separately between continuers 
and interrupters, and continuers and discontinuers using propensity score-based 
inverse probability weighting to adjust for baseline differences. Results: Of the 
827 people included in the sample (mean age: 50 years, ~71% male), 36% continued, 
42% interrupted, and 22% discontinued basal insulin therapy in the year after initia-
tion. Inpatient visits and using fewer classes of non-insulin antidiabetic medica-
tions during baseline were associated with higher likelihoods of interrupting or 
discontinuing insulin therapy. Relative to interrupters and discontinuers, continu-
ers had lower hospitalization rates (continuers:12.7%, interrupters:25.4% [p< 0.001], 
discontinuers:28.4% [p< 0.001]) and lower inpatient costs (continuers:JPY132,013, 
interrupters:JPY225,745 [p= 0.054], discontinuers:JPY320,582 [p= 0.036]), but 
higher pharmacy costs (continuers:JPY158,403, interrupters:JPY134,301 [p= 0.039], 
discontinuers:JPY121,593 [p= 0.002]) in the year after insulin initiation. The total 
healthcare costs were similar for the three cohorts. cOnclusiOns: Substantial 
proportions of people with T2DM initiating basal insulin in Japan interrupt or dis-
continue treatment within the year after initiation, and they have higher rates and 
costs of hospitalizations than continuers. Further research is needed to understand 
reasons behind basal insulin persistence and the implications thereof, to help clini-
cians manage T2DM more effectively.
ated over a 60-year horizon, discounted at 3.5% annually. Results: Mean life 
expectancy of 61.4 years and 22.7 (14.1) undiscounted (discounted) QALYs were 
predicted. Maintaining a 1% reduction in HbA1c was associated with an estimated 
gain of 0.54 QALYs per patient. A 3kg weight loss and 30% reduction in frequency 
of symptomatic hypoglycaemic episodes produced a combined QALY gain of 0.38 
(77% attributable to weight loss), whereas the reverse gave a QALY decrement of 
0.87 (93% attributable to weight gain). cOnclusiOns: The beneficial effects of 
improved glycaemic control on QALYs, achieved through the avoidance of diabetes 
related complications, may be offset by characteristic treatment-specific adverse 
effects, such as weight gain and frequency of hypoglycaemia. The comparative 
weight and hypoglycaemic profiles of available therapies are therefore key to both 
their cost-effectiveness and effectiveness in clinical practice.
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Objectives: Diabetes Mellitus II (DM type II) is characterized by high prevalence 
and severe vascular complications. They are the main cause of disability and death 
in DM patients and lead to grave social and economic consequences. The objective of 
the present study was to assess the impact of selective inhibitors of sodium-glucose 
co-conveyor type 2 on frequency of complications and the costs per QALY compar-
ing with inhibitors dipeptidyl peptidase-4 type. MethOds: Modeling using Global 
«Cardiff diabetes model» in time horizon of 25 years. Strategy I: Line I - selective inhibi-
tors of sodium-glucose co-conveyor type 2 (for example, dapagliflozin), Line II - Line I 
+ metformin; Line III: insulin. Strategy II: Line I - inhibitors dipeptidyl peptidase-4 type 
(for example, sitagliptin); Line II - Line I + metformin; Line III: insulin. The direct medi-
cal costs of medicines, out -patients care and fatal complications were evaluated and 
cost utility analysis (CUA) were held. Results: The direct medical costs for Strategy I 
for 1000 patients during 25 years were 5 309 305 USD: for Strategy II - 5 316 676 USD (7 
371 USD higher). The strategy I helps to prevent the 11 fatal complications among 1000 
DM type II patients. Reducing the frequency of complications provide saving 22 523 
USD for cohort during 25 years. Costs per QALY for Strategy I were on 26 UDS less than 
for Strategy II. The results of CUA were proved by sensitivity analysis. cOnclusiOns: 
Present study has shown that selective inhibitors of sodium-glucose co-conveyor 
type 2 is more cost-effective as a first line therapy thanks to reducing the frequency 
of fatal vascular complications and the costs per QALY.
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Objectives: Hypoglycaemic episodes are a common side-effect of anti-diabetes 
therapy. The impact and associated costs of severe episodes (i.e. episodes that 
the patient is unable to treat themselves) has been extensively reported. There 
is less information about non-severe hypoglycaemic episodes (NSHE). The objec-
tive was to investigate the costs and resource use associated with NSHEs across 
a number of different countries in Europe. MethOds: The ‘Hypoglycaemia in 
Insulin Treated patients’ (HIT) study has recently been completed and reported 
for 11 countries across Europe, reporting data from 6,502 patients. Along with data 
on the frequency and impact of NSHE, the study also collected data on resource 
use associated with NSHEs. Data from ten of the countries were utilized, along 
with published, country specific, cost data to calculate an average NSHE cost in 
each country. Resource use differed for different types of diabetes, costs for Type 
1 diabetes (T1D), and Type 2 diabetes (T2D) are reported separately. Results: 
NSHEs required additional blood glucose tests (3.3-8.2). The numbers differed 
depending on country, type of diabetes (T1D:3.3-7.7; T2D: 1.3-8.2) and whether 
the event was diurnal or nocturnal (min: 1.3-3.7; max: 6.2-8.2). Additionally a 
number (T1D: 0% - 16%; T2D: 3% - 23%), highest in Spain and Germany, of NSHEs 
resulted in contact with healthcare professionals. The average cost (per NSHE) to 
the healthcare system was € 4.34 (T1D - range € 2.10 – € 6.80) ; and € 6.20 (T2D - range 
€ 2.10 – € 11.20). cOnclusiOns: NSHEs pose a substantial burden to healthcare 
systems, and society. While individual episodes incur only a small cost, episodes 
are common, and the frequency of NSHEs means that costs for a country can 
be considerable. In addition to this – the patients will often also bear the cost of 
rescue treatments such as a snack or glucose tablets.
DiaBEtEs/EnDoCRinE DisoRDERs – Patient-Reported outcomes & Patient 
Preference studies
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Objectives: In 2014, the University of Florida College of Pharmacy’s Medication 
Therapy Management (MTM) Communication and Care Center provided an opt-in 
telephone MTM program to eligible Medicare beneficiaries, who were enrolled in 
AvMed Health Plan, a regional Part D plan in Florida. The objective of this study 
was to determine the impact of pharmacist-provided telephone MTM on medica-
tion adherence in elderly patients with hypertension and diabetes. MethOds: 
A retrospective analysis using the AvMed Health Plans (Jan 2013-2014 Dec) was 
conducted for Medicare Advantage Prescription Drug (MAPD) plan beneficiaries 
who received at least two oral anti-diabetics (Diabetes Cohort) and oral anti-hyper-
tensives (Hypertension Cohort), respectively. Adherence, defined by proportion 
of days covered (PDC), was measured using incurred drug claims 6-month before 
and after the MTM program was implemented. Pre-post differences in the PDC 
